In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex |
| |
| Affiliation: | 1. Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques CNRS UMR 5235, Université Montpellier 2, Montpellier, France;2. Biochemistry Division, CSIR-Central Drug Research Institute, LucknowUttar Pradesh, India;3. IFTM University, Lodhipur Rajput, Moradabad Uttar Pradesh, India;4. INSERM U1058 and CHU Arnaud de Villeneuve, Montpellier, France;5. INSERM, DIMNP, Montpellier Cedex 05, France |
| |
| Abstract: | The in vitro susceptibility profile to amikacin, linezolid, clarithromycin, imipenem, cefoxitin, clofazimine and tigecycline was established for 67 strains belonging to the Mycobacterium abscessus complex. Clofazimine and tigecycline were among the most effective drugs, prompting us to assess the effect of a clofazimine and tigecycline combination. Synergistic activity was found in 42% of the 19 isolates tested. The clinical impact of this new drug combination against the M. abscessus complex, as an alternative or sequential medication for the treatment of drug-resistant strains, remains to be addressed. |
| |
| Keywords: | Clofazimine cystic fibrosis drug susceptibility tigecycline |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
